Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
01 févr. 2021 08h05 HE
|
Novan, Inc.
– Topline data on track for targeted readout before the end of Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current...
Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement
29 janv. 2021 16h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has received written notice from The Nasdaq Stock Market LLC...
Novan Provides Enrollment Update and Announces New Corporate Headquarters
19 janv. 2021 09h00 HE
|
Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...
Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
08 janv. 2021 09h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
21 déc. 2020 09h00 HE
|
Novan, Inc.
– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing – – Company targets initiating preclinical Investigational New Drug (IND)...
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
15 déc. 2020 09h00 HE
|
Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...
Novan Receives Approval to Transfer to Nasdaq Capital Market
04 nov. 2020 07h30 HE
|
Novan, Inc.
– Trading on Nasdaq Capital Market is expected to begin on November 5, 2020 – – Company receives additional 180-day grace period, until May 3, 2021, to satisfy the $1.00 bid price requirement to...
Novan Reports Third Quarter 2020 Financial Results and Provides Corporate Update
30 oct. 2020 07h30 HE
|
Novan, Inc.
– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 – – First to demonstrate antiviral effect...
Novan to Present at the Virtual Investor KOL Roundtable
21 oct. 2020 09h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL...
Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
14 oct. 2020 07h00 HE
|
Novan, Inc.
- First demonstration of antiviral effect of nitric oxide-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results...